Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.
Phase 2
- Conditions
- rhabdomyosarcoma
- Registration Number
- JPRN-UMIN000039048
- Lead Sponsor
- Japan Rhabdomyosarcoma Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients with synchronous or metachronous concomitant malignancies 2) patients with prior history of chemotherapy 3) patients with prior history of radiation therapy 4) Female patients who are pregnant or breastfeeding mother 5) patients with contraindication of drugs used in this study 6) patients with Charcot-Marie-Tooth disease, varicella or pentostatin medication 7) Patients with any other inappropriate condition judged by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method